Skip to main content
. 2023 Jun 29;142(16):1371–1386. doi: 10.1182/blood.2022018833

Table 2.

Characteristics of the eculizumab-treated cohort

Mutation/autoantibody
All CaHUS CFH CFHR1 CFI CD46 C3 CFB FHAA Combined Nmd Not CaHUS
n = 243 192 33 1 6 23 10 1 11 5 102 51
Incidence rate (per million per y) 0.41 0.06 0.003 0.01 0.04 0.02 0.003 0.02 0.008 0.24 NR
Age at presentation, y; median (range) 25 (0-80) 21 (1-50) NR
25
42 (4-67) 20 (1-47) 16 (1-51) NR
1
16 (1-69) 16 (2-28) 33 (1-80) 23 (1-76)
Sex (% female) 61 70 NR (F) 71 52 70 NR (F) 36 100 59 51
Trigger, n (%) 59 (31.1) 13 (39) 0 1 (17) 7 (30) 1 (10) 1 6 (55) 0 30 (29) NR
 Infection 29 (15.1) 4 0 1 4 1 0 5 0 14 NR
 Pregnancy 18 (9.5) 5 0 0 1 0 0 0 0 12 NR
Diarrheal prodrome, n (%) 45 (25) 8 (24) 0 0 1 (4) 4 (40) 0 1 (9) 1 (20) 30 (29) 12 (27)
Extrarenal manifestations, n (%) 54 (19) 4 (12) 0 1 (17) 3 (13) 1 (10) 0 2 (18) 0 25 (24) 18 (40)
 Neurological 22 0 0 0 0 0 0 1 0 21 13
 Cardiac 8 4 0 1 1 1 0 0 0 1 2
 Pancreatitis 4 0 0 0 2 0 0 1 0 1 1
Platelet count at presentation, ×109/L; mean (range) 69 (4-329) 104 (31-329) NR
35
76 (25-112) 43 (9-116) 60 (19-157) NR
112
53 (6-96) 67 (26-109) 65 (4-197) 73 (12-336)
Creatinine, μmol/L; mean (range) 488 (18-2435) 660 (50-1989) NR
630
366 (86-652) 470 (79-1377) 465 (37-1709) NR
59
292 (61-1131) 625 (94-1172) 466 (18-2435) 386 (19-1859)
CRP, mg/L; mean (range) 44 (0.5-309) 31 (1-246) NA 38 (5-160) 34 (3-182) 45 (1-136) NR
13
10 (1-34) 18 (7-28) 48 (0.5-309) 83 (1-366)
C3, g/L; mean (range) 0.93 (0.06-2.31) 0.78 (0.06-2.31) NR
0.94
0.88 (0.63-1.09) 1.02 (0.55-1.54) 0.64 (0.08-1.02) NR
0.85
0.75 (0.06-1.23) 1.07 (0.28-1.67) 1.0 (0.22-1.99) 1.0 (0.36-1.79)
Adult systolic blood pressure, mmHg; mean (range) 174 180 (117-229) NR 194 (157-230) 165 (110-220) 168 (145-180) NR 152 (144-160) 147 (140-153) 176 (137-262) 167 (165-270)
Children; % hypertensive 59 67 NR NR 67 40 NR 38 NR 62 70

CRP, C-reactive protein; NR, not relevant (missing or insufficient data).